Articles From: Biologix Hair Inc. Announces 1 for 2 Reverse Split to BioMarin to Attend NewsMakers in the Biotech Industry Conference


http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0893650001&sourceType=1 http://media3.marketwire.com/logos/20130121-logo_BL.jpg TORONTO, ONTARIO --
Sign-up for Biologix Hair Inc. Announces 1 for 2 Reverse Split investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0890292001&sourceType=1 http://media3.marketwire.com/logos/20130121-logo_BL.jpg TORONTO, ONTARIO --
Sign-up for Biologix Hair Inc. Voluntarily Suspends SEC Reporting Obligations investment picks
2014/1/21
SAN RAFAEL, Calif., Jan.
Sign-up for BioMarin Announces Agreement With Repligen for Pre-clinical Compounds investment picks
SAN RAFAEL, Calif., Oct.
Sign-up for BioMarin Announces Exercise by Underwriters of Full Over-Allotment Option investment picks
2014/2/14
SAN RAFAEL, Calif., Feb.
Sign-up for BioMarin Announces FDA Approval for VIMIZIM(TM) (elosulfase alfa) for the Treatment of Patients With Morquio A Syndrome investment picks
2014/2/26
Total Revenue Grows 9.5% in 2013 U.S. Commercial Launch of VIMIZIM™ Underway; Positive CHMP Opinion Received February 20 Financial Highlights ($ in millions, except per share data, unaudited)   Three Months Ended December 31, Twelve Months Ended December 31,   2013 2012 % Change 2013 2012 % Change               Total BioMarin Revenue  $ 146.9  $ 131.9 11.4%  $ 548.5  $ 500.7 9.5% Total BioMarin Revenue              (excluding Aldurazyme Net Product Transfer Revenue) - non-GAAP  148.5  131.2 13.2%  553.4  498.9 10.9% Naglazyme Net Product Revenue  68.7  63.0 9.0%  271.2  257.0
Sign-up for BioMarin Announces Fourth Quarter and Full Year 2013 Financial Results investment picks
SAN RAFAEL, Calif., Nov.
Sign-up for BioMarin Announces French ATU Granted for Vimizim(TM) for the Treatment of Morquio A Syndrome investment picks
2014/3/5
SAN RAFAEL, Calif., March 5, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing on March 4, 2014 of an underwritten public offering of 1,500,000 shares of its common stock.
Sign-up for BioMarin Announces Pricing of Public Offering of Common Stock investment picks
2014/3/4
SAN RAFAEL, Calif., March 4, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 1,500,000 shares of its common stock in an underwritten public offering.
Sign-up for BioMarin Announces Public Offering of Common Stock investment picks
2013/7/25
Total Revenue Growth Exceeds 10 Percent SAN RAFAEL, Calif., July 25, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced financial results for its second quarter ended June 30, 2013.
Sign-up for BioMarin Announces Second Quarter 2013 Financial Results investment picks
2014/1/13
SAN RAFAEL, Calif., Jan.
Sign-up for BioMarin Announces Selection of Factor VIII Gene Therapy Drug Development Candidate BMN 270 for the Treatment of Hemophilia A investment picks
2014/2/11
Potential to Add Fourth MPS Treatment to BioMarin Franchise SAN RAFAEL, Calif., Feb.
Sign-up for BioMarin Announces Selection of NAGLU Fusion Protein Drug Development Candidate BMN 250 for the Treatment of Sanfilippo B (MPS IIIB) investment picks
Total Revenue Grows 6.9% in the Quarter and 8.9% for First Three Quarters of 2013 Financial Highlights ($ in millions, except per share data, unaudited)   Q3 2013 Q3 2012 Percent Change Total BioMarin Revenue  $ 136.9  $ 128.1 6.9% Total BioMarin Revenue (excluding Aldurazyme Net Product Transfer Revenue) - non-GAAP  134.0  124.0 8.1% Naglazyme Net Product Revenue  63.2  62.5 1.1% Aldurazyme BioMarin Net Product Revenue   23.4  23.8 -1.7% Aldurazyme Royalty Revenue (excluding Net Product Transfer Revenue) - non-GAAP  20.5  19.7 4.1% Kuvan Net Product Revenue  43.6  36.4 19.8% Firdapse Net Product Revenue  4.1  3.6 13.9% Net
Sign-up for BioMarin Announces Third Quarter 2013 Financial Results investment picks
2014/3/21
SAN RAFAEL, Calif., March 21, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) , a global leader in providing therapies for rare genetic diseases, today announced the appointment of Dennis J.
Sign-up for BioMarin Appoints Pioneer in Personalized Medicine, Dennis J. Slamon, M.D., Ph.D., to Board of Directors investment picks
2013/9/3
SAN RAFAEL, Calif., Sept.
Sign-up for BioMarin Appoints Richard Ranieri as Senior Vice President, Human Resources and Corporate Affairs investment picks
2014/1/14
SAN RAFAEL, Calif., Jan.
Sign-up for BioMarin Doses First Patient in Phase 2 Trial With BMN 111 for the Treatment of Children With Achondroplasia investment picks
SAN RAFAEL, Calif., Oct.
Sign-up for BioMarin Initiates Phase 3 Trial for BMN 673 for the Treatment of Metastatic gBRCA Breast Cancer investment picks
2014/2/13
12 Abstracts on MPS diseases and 3 on Pompe Disease 10-Year Naglazyme® (galsulfase) Data Suggests Increased Survival of MPS VI Patients SAN RAFAEL, Calif., Feb.
Sign-up for BioMarin Presents 15 Abstracts From Basic Research to Clinical Trials at Lysosomal Disease Network's 10th Annual WORLDSymposium(TM) investment picks
2013/7/25
RECIST Response Rate Increases to 50% in gBRCA Breast Cancer; Study Ongoing SAN RAFAEL, Calif., July 25, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today provided an update on its ongoing Phase 1/2 study for its poly ADP-ribose polymerase (PARP) inhibitor BMN 673 for the treatment of solid tumors.
Sign-up for BioMarin Provides BMN 673 Program Update investment picks
Vimizim: Regulatory applications on track.
Sign-up for BioMarin Provides Highlights Ahead of Research and Development Day investment picks
- Confirmed RECIST Response Rate of 50% in gBRCA Breast Cancer Patients Treated With 1mg/day Phase 3 Dose SAN RAFAEL, Calif., Sept.
Sign-up for BioMarin Provides Updated Phase 1/2 Data on BMN 673 in Breast Cancer at the European Cancer Congress 2013 investment picks
LONDON (MarketWatch) -- Shares of BioMarin Pharmaceutical Inc. (BMRN) jumped 7.6% in premarket trade on Thursday after a report said Swiss drug maker Roche Holding AG (ch:rog) plans to take over the U.S.-listed firm.
Sign-up for BioMarin rallies 7.6% on Roche takeover report investment picks
2014/2/20
SAN RAFAEL, Calif., Feb.
Sign-up for BioMarin Receives Positive Opinion From the CHMP in the European Union for VIMIZIM(TM) (elosulfase alfa) for Morquio A Syndrome investment picks
2013/11/19
SAN RAFAEL, Calif., Nov.
Sign-up for BioMarin Stock Trading Halted Today investment picks
2013/12/4
BioMarin Submits VIMIZIM™ (elosulfase alfa) NDS to Health Canada for the Treatment of Morquio A Syndrome Under Priority Review Status Canada NewsWire Approval would deliver first treatment for Canadians living with ultra-rare, genetic metabolic disorder TORONTO , Dec.
Sign-up for BioMarin Submits VIMIZIM™ (elosulfase alfa) NDS to Health Canada for the Treatment of Morquio A Syndrome Under Priority Review Status investment picks
SAN RAFAEL, Calif., Sept.
Sign-up for BioMarin to Attend NewsMakers in the Biotech Industry Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Biologix Hair Inc. Announces 1 for 2 Reverse Split to BioMarin to Attend NewsMakers in the Biotech Industry Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity